Q32 Bio Financials

QTTB Stock   27.04  0.24  0.88%   
Based on the analysis of Q32 Bio's profitability, liquidity, and operating efficiency, Q32 Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, Q32 Bio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 20.5 M, whereas Total Assets are forecasted to decline to about 190.9 M. Key indicators impacting Q32 Bio's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio9.77.2508
Significantly Up
Slightly volatile
The essential information of the day-to-day investment outlook for Q32 Bio includes many different criteria found on its balance sheet. An individual investor should monitor Q32 Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Q32 Bio.

Net Income

(107.31 Million)

  
Understanding current and past Q32 Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Q32 Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Q32 Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Q32 Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Q32 Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Q32 Bio's management manipulating its earnings.

Q32 Bio Stock Summary

Q32 Bio competes with FTAI Aviation, Willscot Mobile, Air Lease, Pinterest, and U Haul. Q32 Bio is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP438083107 746964105
Older SymbolFIXX
LocationMassachusetts; U.S.A
Business Address830 Winter Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.q32bio.com
Phone781 999 0232

Q32 Bio Key Financial Ratios

Q32 Bio Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets310.6M263.7M35.2M61.8M306.1M190.9M
Other Current Liab9.0M9.8M4.5M8.5M7.0M7.3M
Net Debt(53.8M)(202.0M)(27.3M)838K(37.9M)(39.8M)
Retained Earnings(199.7M)(328.4M)(90.5M)(133.3M)(542.1M)(515.0M)
Accounts Payable2.6M4.7M2.7M1.4M3.2M3.4M
Cash53.8M217.4M32.2M43.9M39.3M67.1M
Other Current Assets3.8M1.7M842K1.9M1.3M1.8M
Total Liab52.1M67.7M124.4M192.5M233.1M244.8M
Total Current Assets266.6M219.6M34.0M46.9M83.9M101.6M
Common Stock3K4K5K1K6K3.1K

Q32 Bio Key Income Statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization6.3M8.9M9.5M2.6M578K549.1K
Gross Profit1.7M2.7M24.4M4.1M578K549.1K
Other Operating Expenses111.6M133.0M36.7M45.9M93.3M72.2M
Operating Income(109.9M)(130.3M)(36.7M)(39.2M)(92.1M)(96.7M)
Ebit(109.9M)(130.3M)(95.8M)(41.5M)(87.1M)(91.4M)
Research Development89.4M100.4M29.9M35.8M62.0M54.0M
Ebitda(103.6M)(121.4M)(86.2M)(38.9M)(86.5M)(90.8M)
Total Operating Expenses105.3M124.1M36.7M45.9M92.7M69.8M
Income Before Tax(103.9M)(128.7M)(37.0M)(42.7M)(87.1M)(91.4M)
Total Other Income Expense Net6.0M1.6M(324K)(3.5M)5.0M5.3M
Net Income(103.9M)(128.7M)(37.6M)(42.8M)(113.0M)(107.3M)
Total Revenue1.7M2.7M34.0M6.7M1.2M1.1M

Q32 Bio Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash15.6M163.7M(12.9M)16.6M5.3M5.0M
Free Cash Flow(113.2M)(98.1M)(33.1M)(13.4M)(96.5M)(91.6M)
Change In Working Capital463K11.5M3.7M26.9M(7.2M)(6.8M)
Begin Period Cash Flow38.2M53.8M45.9M32.9M34.0M39.8M
Other Cashflows From Financing Activities(51.8M)204.9M52.1M(2.5M)101.3M106.4M
Depreciation6.3M8.9M47K370K578K549.1K
Other Non Cash Items22.9M29.3M102K876K23.4M24.5M
Capital Expenditures21.8M3.7M157K2.5M228K216.6K
Total Cash From Operating Activities(91.4M)(94.3M)(33.0M)(11.0M)(96.2M)(91.4M)
Net Income(103.9M)(128.7M)(37.6M)(42.8M)(113.0M)(107.3M)
Total Cash From Financing Activities158.2M53.1M20.1M30.1M184K174.8K
End Period Cash Flow53.8M217.4M33.0M49.5M39.3M68.0M

Q32 Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Q32 Bio's current stock value. Our valuation model uses many indicators to compare Q32 Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Q32 Bio competition to find correlations between indicators driving Q32 Bio's intrinsic value. More Info.
Q32 Bio is currently regarded as top stock in operating margin category among its peers. It also is currently regarded number one company in current valuation category among its peers reporting about  90,427,115  of Current Valuation per Operating Margin. At present, Q32 Bio's Operating Profit Margin is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Q32 Bio's earnings, one of the primary drivers of an investment's value.

Q32 Bio Systematic Risk

Q32 Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Q32 Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Q32 Bio correlated with the market. If Beta is less than 0 Q32 Bio generally moves in the opposite direction as compared to the market. If Q32 Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Q32 Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Q32 Bio is generally in the same direction as the market. If Beta > 1 Q32 Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Q32 Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Q32 Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Q32 Bio growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.002017)

At present, Q32 Bio's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Q32 Bio November 22, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Q32 Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Q32 Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Q32 Bio based on widely used predictive technical indicators. In general, we focus on analyzing Q32 Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Q32 Bio's daily price indicators and compare them against related drivers.

Complementary Tools for Q32 Stock analysis

When running Q32 Bio's price analysis, check to measure Q32 Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Q32 Bio is operating at the current time. Most of Q32 Bio's value examination focuses on studying past and present price action to predict the probability of Q32 Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Q32 Bio's price. Additionally, you may evaluate how the addition of Q32 Bio to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Global Correlations
Find global opportunities by holding instruments from different markets